Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does VEDOLIZUMAB Cause Swollen joint count increased? 247 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 247 reports of Swollen joint count increased have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.3% of all adverse event reports for VEDOLIZUMAB.

247
Reports of Swollen joint count increased with VEDOLIZUMAB
0.3%
of all VEDOLIZUMAB reports
246
Deaths
191
Hospitalizations

How Dangerous Is Swollen joint count increased From VEDOLIZUMAB?

Of the 247 reports, 246 (99.6%) resulted in death, 191 (77.3%) required hospitalization, and 190 (76.9%) were considered life-threatening.

Is Swollen joint count increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 247 reports have been filed with the FAERS database.

What Other Side Effects Does VEDOLIZUMAB Cause?

Off label use (21,017) Colitis ulcerative (13,455) Crohn's disease (9,759) Drug ineffective (8,424) Diarrhoea (7,493) Abdominal pain (6,401) Fatigue (5,477) Haematochezia (5,215) Frequent bowel movements (4,527) Arthralgia (4,028)

What Other Drugs Cause Swollen joint count increased?

METHOTREXATE (2,068) ABATACEPT (2,032) TOCILIZUMAB (1,987) RITUXIMAB (1,973) ADALIMUMAB (1,933) DICLOFENAC (1,916) LEFLUNOMIDE (1,907) FOLIC ACID (1,898) PREDNISONE (1,882) ALENDRONATE (1,880)

Which VEDOLIZUMAB Alternatives Have Lower Swollen joint count increased Risk?

VEDOLIZUMAB vs VELAGLUCERASE ALFA VEDOLIZUMAB vs VELCADE VEDOLIZUMAB vs VELETRI VEDOLIZUMAB vs VELIPARIB VEDOLIZUMAB vs VEMURAFENIB

Related Pages

VEDOLIZUMAB Full Profile All Swollen joint count increased Reports All Drugs Causing Swollen joint count increased VEDOLIZUMAB Demographics